Oral anticancer drugs: Mechanisms of low bioavailability and strategies for improvement

Clinical Pharmacokinetics

Volumn 52, Issue 6, 2013, Pages 399-414

  Stuurman, Frederik E ^a   Nuijen, Bastiaan ^b   Beijnen, Jos H ^b,c   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; DEXVERAPAMIL; DOCETAXEL; ELACRIDAR; ETOPOSIDE; FIRTECAN; FLUOROURACIL; GEMCITABINE; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IDARUBICIN; IRINOTECAN; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RITONAVIR; TEMOZOLOMIDE; TOPOTECAN; UFT; URACIL; VALSPODAR;

BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; LIPOPHILICITY; MAXIMUM TOLERATED DOSE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG STABILITY; FOOD-DRUG INTERACTIONS; HUMANS; SOLUBILITY;

EID: 84878676892     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0040-2     Document Type: Review

References (235)

1. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87(9):933-7.
2. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):110-5.
3. Bridges JFP, Mohamed AF, Finnern HW, et al. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012;77(1):224-31.
4. Benjamin L, Cotté F-E, Philippe C, et al. Physicians' preferences for prescribing oral and intravenous anticancer drugs: a discrete choice experiment. Eur J Cancer. 2012;48(6):912-20.
5. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56-66.
6. Mastroianni CM, Viscomi C, Ceniti S, et al. Preferences of patients with advanced colorectal cancer for treatment with oral or intravenous chemotherapy. Patient. 2008;1(3):181-7.
7. Lima PR, del Giglio A. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl). 2005;14(2):151-4.
8. Bonastre J, Jan P, Barthe Y, et al. Metastatic breast cancer: we do need primary cost data. Breast. 2012;21(3):384-8.
9. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-36.
10. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.
11. Gelderblom H, Verweij J, Nooter K, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.
12. Bhatt RS, Merchan J, Parker R, et al. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 2010;116(7):1751-6.
13. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther. 1996;60(6):601-7.
14. US Food and Drug Administration. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products - general considerations; 2003. http://www.fda.gov/downloads/Drugs/./Guidances/ucm070124. pdf. Accessed 14 Feb 2013
15. US Food and Drug Administration. Code of Federal Regulations. Title 21: food and drugs. Part 320 - bioavailability and bioequivalence studies. 320.21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart= 320. Accessed 14 Feb 2013
16. Pond SM, Tozer TN. First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet. 1984;9(1):1-25.
17. Burton PS, Goodwin JT, Vidmar TJ, et al. Predicting drug absorption: how nature made it a difficult problem. J Pharmacol Exp Ther. 2002;303(3):889-95.
18. Noyes AS, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19:930-4.
19. Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15(1):11-22.
20. Evans DF, Pye G, Bramley R, et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29(8):1035-41.
21. Ewe K, Schwartz S, Petersen S, et al. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci. 1999;44(7):1434-9.
22. Press AG, Hauptmann IA, Hauptmann L, et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment pharmacol Ther. 1998;12(7):673-8.
23. Washington N, Washington C, Wilson C. Small intestine: transit and absorption of drugs. In: Physiological pharmaceutics. London: Taylor & Francis; 1989. p. 71-90.
24. European Medicines Agency. Iressa. Summary of product characteristics (SPC). http://www.medicines.org.uk/emc/medicine/22104/SPC/. Accessed 27 May 2012.
25. European Medicines Agency. Tyverb. Summary of product characteristics (SPC). http://www.medicines.org.uk/emc/medicine/20929/SPC/tyverb/. Accessed 27 May 2012.
26. Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49(6):700-9.
27. Joel SP, Clark PI, Slevin ML. Stability of the i.v. and oral formulations of etoposide in solution. Cancer Chemother Pharmacol. 1995;37(1-2):117-24.
28. Joel SP, Clark PI, Heap L, et al. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol. 1995;37(1-2):125-33.
29. Toffoli G, Corona G, Basso B, et al. Pharmacokinetic optimisation of treatment with oral etoposide. Clinical Pharmacokinet. 2004;43(7):441-66.
30. Adair CG, Bridges JM, Desai ZR. Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol. 1986;17(1):99-102.
31. Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
32. Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci. 2010;99(12):4940-54.
33. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49.
34. van Hoogevest P, Liu X, Fahr A. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. Expert Opin Drug Deliv. 2011;8(11):1481-500.
35. Yáñez JA, Wang SWJ, Knemeyer IW, et al. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011;63(10-11):923-42.
36. Chan LMS, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004;21(1):25-51.
37. van Herwaarden AE, van Waterschoot RAB, Schinkel AH. How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol Sci. 2009;30(5):223-7.
38. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83(8):1084-103.
39. Kuppens IELM, Breedveld P, Beijnen JH, et al. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest. 2005;23(5):443-64.
40. Bardelmeijer HA, Ouwehand M, Beijnen JH, et al. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs. 2004;22(3):219-29.
41. van Waterschoot RAB, Schinkel AH. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev. 2011;63(2):390-410.
42. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3-29.
43. Ni L-N, Li J-Y, Miao K-R, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2011;28(1):265-9.
44. Dohse M, Scharenberg C, Shukla S, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010;38(8):1371-80.
45. Bansal T, Mishra G, Jaggi M, et al. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci. 2009;36(4-5):580-90.
46. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 2002;62(21):6158-64.
47. Lacayo NJ, Duran GE, Sikic BI. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. J Exp Ther Oncol. 2003;3(3):127-35.
48. Banna GL, Collovà E, Gebbia V, et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev. 2010;36(8):595-605.
49. Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res. 2010;16(1):130-40.
50. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev. 2002;54(10):1311-31.
51. Huisman MT, Chhatta A, van Tellingen O, et al. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005;116(5):824-9.
52. Lai L, Tan TMC. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002;361(Pt 3):497-503.
53. Wittgen HGM, van den Heuvel JJMW, Krieger E, et al. Phenylalanine 368 of multidrug resistance-associated protein 4 (MRP4/ABCC4) plays a crucial role in substrate-specific transport activity. Biochem Pharmacol. 2012;84(3):366-73.
54. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61(8):3458-64.
55. Fetsch P, Abati A, Litman T, et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 2006;235(1):84-92.
56. Dankers AC, Sweep FCGJ, Pertijs JCLM, et al. Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012;349(2):551-63.
57. Anger GJ, Cressman AM, Piquette-Miller M. Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes. PloS ONE. 2012;7(4):e35027.
58. Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999;59(17):4237-41.
59. Vlaming MLH, van Esch A, van de Steeg E, et al. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab Dispos. 2011;39(8):1338-44.
60. Marchetti S, de Vries N, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008;7(8):2280-7.
61. Balabanov S, Gontarewicz A, Keller G, et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro. PloS ONE. 2011;6(4):e19164.
62. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008;36(4):695-701.
63. Chen Y-J, Huang W-C, Wei Y-L, et al. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PloS ONE. 2011;6(6):e21428.
64. Seamon JA, Rugg CA, Emanuel S, et al. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther. 2006;5(10):2459-67.
65. Masuda S, Uemoto S, Hashida T, et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther. 2000;68(1):98-103.
66. Vasconcelos FC, Silva KL, Souza PSD, et al. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom. 2011;80(3):158-66.
67. Deenen MJ, Cats A, Beijnen JH, et al. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist. 2011;16(6):820-34.
68. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17.
69. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001;50(Suppl 1):S3-11.
70. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54(10):1271-94.
71. Gorski JC, Vannaprasaht S, Hamman M, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74(3):275-87.
72. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75(3):172-83.
73. Huang S-M, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Oncol. 2008;48(6):662-70.
74. Mandlekar S, Hong J-L, Kong A-NT. Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr Drug Metab. 2006;7(6):661-75.
75. Baker SD, Khor SP, Adjei AA, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol. 1996;14(12):3085-96.
76. Spector T, Harrington JA, Porter DJ. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol. 1993;46(12):2243-8.
77. Koolen SLW, Witteveen PO, Jansen RS, et al. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2011;17(18):6071-82.
78. Christophidis N, Vajda FJ, Lucas I, et al. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet. 1978;3(4):330-6.
79. Schöffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004;15(2):85-106.
80. Harvey VJ, Slevin ML, Joel SP, et al. The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol. 1986;16(2):178-81.
81. Hande KR, Krozely MG, Greco F, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol. 1993;11(2):374-7.
82. Chabot GG, Armand JP, Terret C, et al. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. J Clin Oncol. 1996;14(7):2020-30.
83. Sharma S. Patient selection for oral chemotherapy. Oncology (Williston Park). 2001;15(1 Suppl 2):33-5.
84. Dias VC, Madsen KL, Mulder KE, et al. Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. Dig Dis Sci. 1998;43(10):2227-36.
85. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park). 2005;19(8):1057-69.
86. Lorusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18(10):2954-63.
87. US Food and Drug Administration. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Guidance for industry 2003. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf. Accessed 14 Feb 2013
88. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharm Res. 2004;56(2):163-84.
89. Malaguarnera G, Leggio F, Vacante M, et al. Probiotics in the gastrointestinal diseases of the elderly. J Nutr Health Aging. 2012;16(4):402-10.
90. Grassi M, Petraccia L, Mennuni G, et al. Changes, functional disorders, and diseases in the gastrointestinal tract of elderly. Nutr Hosp. 2011;26(4):659-68.
91. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18(11):837-51.
92. Ling J, Fettner S, Lum BL, et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008;19(2):209-16.
93. Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27(8):1191-6.
94. Martin P, Oliver S, Kennedy S-J, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther. 2012;34(1):221-37.
95. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs. 2006;17(3):353-8.
96. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet. 2004;43(15):1127-56.
97. Bosch TM, Huitema ADR, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12(19):5786-93.
98. Baker SD, Verweij J, Cusatis GA, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85(2):155-63.
99. Deenen MJ, Cats A, Beijnen JH, et al. Part 1: background, methodology, and clinical adoption of pharmacogenetics. Oncologist. 2011;16(6):811-9.
100. Deenen MJ, Cats A, Beijnen JH, et al. Part 3: pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist. 2011;16(7):992-1005.
101. Deenen MJ, Cats A, Beijnen JH, et al. Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. Oncologist. 2011;16(7):1006-20.
102. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281-302.
103. Savolainen M, Kogermann K, Heinz A, et al. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm. 2009;71(1):71-9.
104. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol. 2009;61(12):1571-86.
105. Thakral NK, Ray AR, Bar-Shalom D, et al. Soluplus-solubilized citrated camptothecin-a potential drug delivery strategy in colon cancer. AAPS PharmSciTech. 2012;13(1):59-66.
106. Chen C, Huang X, Cai H, et al. Anti-proliferation and anti-angiogenesis of curcumin-K30 solid dispersion. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35(10):1029-36.
107. Moes JJ, Koolen SLW, Huitema DR, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm. 2011;420(2):244-50.
108. Marchetti S, Stuurman F, Koolen S, et al. Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors. J Clin Oncol. 2012;30 (suppl; abstr 2550).
109. Liu X, Sun J, Chen X, et al. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. J Pharm Pharmacol. 2012;64(6):775-82.
110. Lush RM, McCune JS, Tetteh L, et al. The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol. 2005;56(6):578-84.
111. Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol. 1994;12(9):1754-63.
112. Zhou XJ, Boré P, Monjanel S, et al. Pharmacokinetics of navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol. 1991;29(1):66-70.
113. Zhou XJ, Zhou-Pan XR, Favre R, et al. Relative bioavailability of two oral formulations of navelbine in cancer patients. Biopharm Drug Dispos. 1994;15(7):577-86.
114. Bourgeois H, Vermorken J, Dark G, et al. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol. 2007;60(3):407-13.
115. Eckardt JR, von Pawel J, Pujol J-L, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086-92.
116. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19(6):1743-9.
117. Witterland AH, Koks CH, Beijnen JH. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci. 1996;18(5):163-70.
118. Hong YS, Kim K-P, Lim H-S, et al. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel. Invest New Drugs. Epub 2012 Jun 14.
119. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3-4):278-87.
120. Sachan R, Khatri K, Kasture SB. Self-emulsifying drug delivery system a novel approach for enhancement of bioavailability. Int J Pharm Tech Res. 2010;2(3):1738-45.
121. Gibaud S, Attivi D. Microemulsions for oral administration and their therapeutic applications. Expert Opin Drug Deliv. 2012;9(8):937-51.
122. Yang S, Gursoy RN, Lambert G, et al. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res. 2004;21(2):261-70.
123. Oostendorp RL, Buckle T, Lambert G, et al. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Invest New Drugs. 2010;29:768-76.
124. Chaurasiya A, Singh AK, Jain GK, et al. Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes. J Microencapsul. 2012;4:1-13.
125. Attivi D, Ajana I, Astier A, et al. Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm. 2010;36(4):421-7.
126. Lu J-L, Wang J-C, Zhao S-X, et al. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur J Pharm Biopharm. 2008;69(3):899-907.
127. Aamdal S, Awada A, Evans J, et al. First-in-man study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumours [abstract no. 496P]. Ann Oncol. 2008; 19(suppl 8):viii153-65. doi: 10.1093/annonc/mdn508.
128. Bergman AM, Adema AD, Balzarini J, et al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs. 2011;29(3):456-66.
129. Gao P, Rush BD, Pfund WP, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 2003;92(12):2386-98.
130. Fenyvesi F, Kiss T, Fenyvesi E, et al. Randomly methylated β-cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco-2 cell monolayer. J Pharm Sci. 2011;100(11):4734-44.
131. Agüeros M, Zabaleta V, Espuelas S, et al. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release. 2010;145(1):2-8.
132. Lim J, Simanek EE. Triazine dendrimers as drug delivery systems: From synthesis to therapy. Adv Drug Deliv Rev. 2012;64(9):826-35.
133. Kolhatkar RB, Swaan P, Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm Res. 2008;25(7):1723-9.
134. Dahmani FZ, Yang H, Zhou J, et al. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. Eur J Pharm Sci. 2012;47(1):179-89.
135. Nekkanti V, Venkateswarlu V, Ansari KA, et al. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration. Curr Drug Deliv. 2011;8(6):661-6.
136. Wang X, Fan J, Liu Y, et al. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 2011;419(1-2):339-46.
137. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000;92(20):1651-6.
138. Sparreboom A, Van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031-5.
139. Van Asperen J, Van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer. 1997;76(9):1181-3.
140. Van Asperen J, Van Tellingen O, Van der Valk M, et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res. 1998;4(10):2293-7.
141. Rottenberg S, Nygren AOH, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A. 2007;104(29):12117-22.
142. Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother. 2004;38(10):1631-4.
143. Malingré MM, Schellens JH, Van Tellingen O, et al. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anticancer Drugs. 2000;11(10):813-20.
144. Maliepaard M, Van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001;7(4):935-41.
145. Shonukan O, Dantzig AH, Kloeker-Rhoades S, et al. Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas. Hematol Meet Rep. 2009;3(1):69.
146. Chi KN, Chia SK, Dixon R, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005;23(4):311-5.
147. Kelly RJ, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2011;17(3):569-80.
148. Joo KM, Song SY, Park K, et al. Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors. Int J Oncol. 2008;33(4):705-12.
149. ® in combination with paclitaxel in solid tumors. Oncologist. 2012;17(4):512.
150. Jin J, Bi H, Hu J, et al. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Biopharm Drug Dispos. 2010;31(4):264-8.
151. Gu X, Ren Z, Tang X, et al. Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors. Bioorg Med Chem. 2012;20(8):2540-8.
152. Wesołowska O. Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1. Acta Biochim Pol. 2011;58(4):433-48.
153. Yokooji T, Murakami T, Yumoto R, et al. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2007;59(9):1263-70.
154. González-Lobato L, Real R, Prieto JG, et al. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010;644(1-3):41-8.
155. Barrera B, Otero JA, Egido E, et al. The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP. Antimicrob Agents Chemother. 2012;56(7):3535-43.
156. Pick A, Müller H, Mayer R, et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem. 2011;19(6):2090-102.
157. Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007;96(12):3226-35.
158. Helgason HH, Kruijtzer CMF, Huitema ADR, et al. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br J Cancer. 2006;95(7):794-800.
159. Kruijtzer CMF, Boot H, Beijnen JH, et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol. 2003;14(2):197-204.
160. Kruijtzer CMF, Schellens JHM, Mezger J, et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(23):4508-16.
161. Oostendorp RL, Huitema A, Rosing H, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res. 2009;15(12):4228-33.
162. Santos JR, Moltó J, Llibre JM, et al. Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile. PloS ONE. 2012;7(5):e37442.
163. Bánhegyi D, Katlama C, Da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012. Epub 2012 Feb 2.
164. Blick G, Greiger-Zanlungo P, Gretz S, et al. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study. Int J STD AIDS. 2012;23(3):e18-22.
165. Baccanari DP, Davis ST, Knick VC, et al. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci U S A. 1993;90(23):11064-8.
166. Takechi T, Fujioka A, Matsushima E, et al. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002;38(9):1271-7.
167. Anttila MI, Sotaniemi EA, Kairaluoma MI, et al. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol. 1983;10(3):150-3.
168. Yamashita K, Yada H, Ariyoshi T. Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. J Toxicol Sci. 2004;29(2):155-66.
169. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53(17):4004-9.
170. Schilsky RL, Levin J, West WH, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002;20(6):1519-26.
171. Spector T, Cao S. A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil. Clin Colorectal Cancer. 2010;9(1):52-4.
172. Kobayakawa M, Kojima Y. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther. 2011;4:193-201.
173. ® (tegafur-uracil) oral 5-FU therapy. http://www.merckserono.com/en/products/oncology/colorectal-cancer/uft/uft.html. Accessed 9 Jun 2012.
174. Alani AWG, Rao DA, Seidel R, et al. The effect of novel surfactants and Solutol HS 15 on paclitaxel aqueous solubility and permeability across a Caco-2 monolayer. J Pharm Sci. 2010;99(8):3473-85.
175. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1-2):1-11.
176. Fenyvesi F, Fenyvesi E, Szente L, et al. P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci. 2008;34(4-5):236-42.
177. Zhang Y, Wang Q-S, Cui Y-L, et al. Changes in the intestinal absorption mechanism of icariin in the nanocavities of cyclodextrins. Int J Nanomed. 2012;7:4239-49.
178. Ishikawa M, Yoshii H, Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci Biotechnol Biochem. 2005;69(1):246-8.
179. Marigny K, Aubin F, Burgot G, et al. Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer Chemother Pharmacol. 2005;55(3):244-50.
180. De Jong RS, Slijfer EA, Uges DR, et al. Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile. Br J Cancer. 1997;76(11):1480-3.
181. De Jong RS, Mulder NH, Uges DR, et al. Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br J Cancer. 1997;75(11):1660-6.
182. Kim HK, Lin CC, Parker D, et al. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B Biomed Sci Appl. 1997;703(1-2):225-33.
183. Tsang LL, Quarterman CP, Gescher A, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27(5):342-6.
184. Diez BD, Statkevich P, Zhu Y, et al. Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemother Pharmacol. 2010;65(4):727-34.
185. Marzolini C, Decosterd LA, Shen F, et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol. 1998;42(6):433-40.
186. European Medicines Agency. Assessment report for temozolomide. EMA/51724/2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Public-assessment-report/human/001124/WC500073303.pdf. Accessed 29 Jan 2013.
187. Schellens JHM. Capecitabine. Oncologist. 2007;12(2):152-5.
188. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999;5(7):1696-702.
189. Van Der Heyden SA, Highley MS, De Bruijn E, et al. Pharmacokinetics and bioavailability of oral 5′-deoxy-5-fluorouridine in cancer patients. Br J Cancer. 1999;47(4):351-6.
190. Ochoa L, Hurwitz HI, Wilding G, et al. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol. 2000;11(10):1313-22.
191. Nemunaitis J, Eager R, Twaddell T, et al. Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. J Clin Oncol. 2000;18(19):3423-34.
192. Hofheinz R-D, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579-88.
193. Koukourakis GV, Zacharias G, Tsalafoutas J, et al. Capecitabine for locally advanced and metastatic colorectal cancer: a review. World J Gastrointest Oncol. 2010;2(8):311-21.
194. Shipley LA, Brown TJ, Cornpropst JD, et al. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos. 2006;20(6):849-55.
195. Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(5 Suppl 10):3-15.
196. Veltkamp SA, Jansen RS, Callies S, et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res. 2008;14(11):3477-86.
197. Bender DM, Bao J, Dantzig AH, et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem. 2009;52(22):6958-61.
198. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9(3):491-8.
199. Stuurman FE, Voest EE, Awada A, et al. Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumours. Eur J Cancer Supp. 2010;8(7):135.
200. Berlin J, Benson AB, Ruben P, et al. Phase I safety, pharmacokinetic (PK), and bioavailability (F) study of a semi-solid matrix (SSM) formulation of oral irinotecan in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2003;22(abstr 521).
201. Bansal T, Awasthi A, Jaggi M, et al. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sci. 2008;83(7-8):250-9.
202. Haaz MC, Rivory L, Riché C, et al. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 1998;58(3):468-72.
203. Pommier Y, Topoisomerase I. Inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789-802.
204. Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol. 2009;27(27):4599-604.
205. Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today. 2007;12(19-20):838-43.
206. European Medicines Agency/Committee for Medicinal Products for Human Use (CHMP) Think-Tank Group on Innovative Drug Development. Medicines and emerging science. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/ general/general-content-000339.jsp&mid=WC0b01ac05800baed8. Accessed 10 Jun 2012.
207. Findlay M, Von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol. 2008;19(2):212-22.
208. Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85-96.
209. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5(5):268-78.
210. Peterson PN, Shetterly SM, Clarke CL, et al. Health literacy and outcomes among patients with heart failure. JAMA. 2011;305(16):1695-701.
211. Klümpen H-J, Samer CF, Mathijssen RHJ, et al. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37(4):251-60.
212. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474-83.
213. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935-42.
214. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20(9):2240-50.
215. Meerum Terwogt JM, Malingré MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999;5(11):3379-84.
216. Chu Z, Chen J-S, Liau C-T, et al. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs. 2008;19(3):275-81.
217. Malingré MM, Beijnen JH, Rosing H, et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer. 2001;84(1):42-7.
218. Koolen SLW. Intravenous-to-oral switch in anticancer chemotherapy; focus on taxanes and gemcitabine [dissertation]. Utrecht: University of Utrecht; 2011. p. 105-16.
219. Hanmi Pharmaceutical Company. Clinical trial to determine the maximum tolerated dose and to assess the safety and pharmacokinetic profile of oral paclitaxel in patients with advanced solid cancer [NCT01491204]. US National Institutes of Health. http://www.clinicaltrials.gov. Accessed 10 Jul 2012.
220. Malingré MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol. 2001;19(4):1160-6.
221. Malingré MM, Ten Bokkel Huinink WW, Mackay M, et al. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. Eur J Cin Pharmacol. 2001;57(4):305-7.
222. Koolen SLW, Oostendorp RL, Beijnen JH, et al. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol. 2010;69(5):465-74.
223. Kuppens IELM, Bosch TM, Van Maanen MJ, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol. 2005;55(1):72-8.
224. Hande K, Messenger M, Wagner J, et al. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res. 1999;5(10):2742-7.
225. Yong WP, Desai AA, Innocenti F, et al. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007;60(6):811-9.
226. Reif S, Nicolson MC, Bisset D, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol. 2002;58(7):491-4.
227. Herben VM, Rosing H, Ten Bokkel Huinink WW, et al. Oral topotecan: bioavailability and effect of food co-administration. Br J Cancer. 1999;80(9):1380-6.
228. Kuppens IELM, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res. 2007;13(11):3276-85.
229. Kruijtzer CMF, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol. 2002;20(13):2943-50.
230. European Medicines Agency. Hycamtin. Summary of product characteristics (SPC). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000123/human-med-000823.jsp&mid=WC0b01ac058001d124. Accessed 3 Aug 2012.
231. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993;24(4):275-88.
232. Bauer KS, Karp JE, Garimella TS, et al. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leuk Res. 2005;29(3):263-71.
233. Pea F, Damiani D, Michieli M, et al. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. Eur J Clin Pharmacol. 1999;55(5):361-8.
234. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215-37.
235. Saif MW, Rosen LS, Saito K, et al. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. Anticancer Res. 2011;31(2):625-32.